The INSIGHT 2 trial was designed to assess the efficacy and safety of the combination of tepotinib (500 mg daily) with osimertinib (80 mg daily) or tepotinib monotherapy in metastatic NSCLC patients with EGFR activating mutations who progressed on first-line treatment with EGFR TKIs, and who had confirmed MET amplification by FISH method in tissue biopsy (MET gene copy number of ≥5 or MET-to-CEP7 ratio of ≥2) or by next-generation sequencing in liquid biopsy (MET plasma gene copy number ≥ 2). Here, MET is linked to non-small cell lung carcinoma.